C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

February 28, 2010

Study Completion Date

May 31, 2010

Conditions
Hereditary Angioedema
Interventions
DRUG

C1 Esterase Inhibitor

Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv

Trial Locations (14)

17033

Contact CSL Behring for facility details, Hershey

30342

Contact CSL Behring for facility details, Atlanta

33331

Contact CSL Behring for facility details, Weston

55446

Contact CSL Behring for facility details, Plymouth

57702

Contact CSL Behring for facility details, Rapid City

69131

Contact CSL Behring for facility details, Omaha

71130

Contact CSL Behring for facility details, Shreveport

74133

Contact CSL Behring for facility details, Tulsa

75230

Contact CSL Behring for facility details, Dallas

83404

Contact CSL Behring for facility details, Idaho Falls

97401

Contact CSL Behring for facility details, Eugene

60612-3244

Contact CSL Behring for facility details, Chicago

02115

Contact CSL Behring for facility details, Boston

KIY 4G2

Contact CSL Behring for facility details, Ottawa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY